NCT03531736View on ClinicalTrials.gov

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Myeloid Diseases
Interventions
DRUG

Antithymocyte globulin (Rabbit)

ATG (2 mg/kg/d IV on days-8 through -7)

DRUG

fludarabine

fludarabine (30 mg/m2/d on days -5 through -2)

RADIATION

total body irradiation

TBI 200 cGy (days -2 and -1) given post stem cell infusion

DRUG

cyclophosphamide

cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)

DRUG

Rituxan

Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER